Navigation Links
Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
Date:11/10/2008

PRINCETON, N.J., Nov. 10 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS), Roche (SWX: ROG) and InterMune, Inc. (Nasdaq: ITMN) today announced that the first patients have been dosed in an innovative clinical trial in patients chronically infected with the hepatitis C virus (HCV). The trial (run in centers in Australia and New Zealand) is the first to investigate the combination of two oral antiviral molecules in the absence of interferon.

The initial study will evaluate the safety and combined antiviral activity of R7227 (ITMN-191), a protease inhibitor, and R7128, a polymerase inhibitor, in 14 days of combination therapy in treatment-naive patients infected with HCV genotype 1.

This direct antiviral combination study represents an important first step in evaluating the therapeutic potential of an all-oral, interferon-free combination treatment for HCV. Roche is uniquely positioned to develop all-oral combination studies in HCV through its collaborations with InterMune and Pharmasset, which provide access to both protease and polymerase inhibitors, respectively.

With InterMune, Roche is developing R7227, an HCV protease inhibitor compound to be used in combination with PEGASYS(R) (peginterferon alfa-2a) and COPEGUS(R) (ribavirin), the current standard of care (SOC). Concurrently with Pharmasset, Roche is developing R7128, an HCV RNA polymerase inhibitor, also for therapy in combination with PEGASYS(R) and COPEGUS(R). Both of these molecules have successfully completed Phase 1 monotherapy
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. InterMune Announces Start of 14-Day Triple Combination Study of ITMN-191 in Patients With Chronic Hepatitis C
2. InterMune Announces Receipt of Fast Track Designation for Pirfenidone From FDA
3. InterMune Announces Progress on Pirfenidone in IPF
4. InterMune Provides Additional Information on ITMN-191 (R7227) MAD Study Results
5. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
6. InterMune Announces Start of Phase 1b Trial of ITMN-191
7. InterMune Announces Approval of Clinical Trial Authorization for Phase 1b Trial of ITMN-191
8. Richard E.T. Smith, Ph.D. Joins Pharmasset as Vice President of Investor Relations and Corporate Communications
9. Pharmasset to Present at the UBS Global Life Sciences Conference on Wednesday, September 24th
10. Pharmasset Reports Financial Results for Quarter Ended June 30, 2008
11. Pharmasset Reports Preliminary Results of a 4-week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)...  Tandem Diabetes Care®, Inc. (NASDAQ: TNDM ... the t:slim® and t:flex™ Insulin Pumps, today announced ... with Dexcom, Inc. to allow the integration of ... G5 and G6 continuous glucose monitoring ("CGM") systems. ... with Dexcom,s future CGM systems is an important ...
(Date:7/30/2015)... VANCOUVER , July 30, 2015  OncoGenex Pharmaceuticals, ... will report its second quarter 2015 financial results on ... conference call and live webcast at 4:30 p.m. Eastern ... development programs and a general corporate update. ... Investor Relations page of the OncoGenex website at ...
(Date:7/30/2015)... July 30, 2015 Tianyin Pharmaceutical Inc. (NYSE ... that specializes in the patented biopharmaceutical, modernized traditional Chinese ... provided updates regarding the notice it received on May ... indicating that the Company was below certain of the ... 134 and 1101 of the NYSE MKT Company Guide, ...
Breaking Medicine Technology:Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 3TPI Provides Update Regarding Non-Compliance with NYSE MKT Continued Listing Requirements 2
... Given the narrow initial public offering window, declining venture ... become the exit of choice for many biopharmaceutical companies. In ... was higher, but it still wasn,t the flood of deals ... Another not-so-positive trend for biotech in 2011 was ...
... Independa™ announced today that it has closed ... that surpassed the target of $2.2 million indicating strong ... solutions that enhance independence for older adults. ... top of $1.6 million in seed-round venture capital funding ...
Cached Medicine Technology:Biopharma M&A Trends Hold Steady, But Deals Declined in 2011 2Independa Closes Convertible Note Funding at $2.35 Million 2Independa Closes Convertible Note Funding at $2.35 Million 3
(Date:7/31/2015)... ... July 31, 2015 , ... ... magazine. What are the STASH awards? The Significant Technological Achievements in Secretive ... cannabis-cultivation community as well as tried-and-true products that have stood the test of ...
(Date:7/31/2015)... ... 01, 2015 , ... Super Bowl 50 will emanate from Levi’s Stadium in Santa ... year is the Super Bowl. In the two weeks that separate the conference championships and ... The 2016 Super Bowl game will mark the 50th time it has been held and ...
(Date:7/31/2015)... VA (PRWEB) , ... July 31, 2015 , ... ... introduced its new store run by GoodThreads. The store can be accessed by ... and designs, many of which are customizable. The best part: whenever a product ...
(Date:7/31/2015)... ... July 31, 2015 , ... Jacksonville-based drug ... new True North Conference Center. The medical community, social workers, law enforcement, and ... be more aligned in the effort to better understand and combat sex trafficking. ...
(Date:7/31/2015)... New York, NY (PRWEB) , ... July 31, 2015 , ... ... Richard Rodgers Theatre . Those looking to catch a new and refreshing show ... has won numerous awards and achievements including an Obie Award, Outer Critics Circle Award, ...
Breaking Medicine News(10 mins):Health News:The High Times S.T.A.S.H. Awards Are in, Guess Who Took Home the Prize for “Best Grow System” 2Health News:Cheap 2016 Super Bowl Tickets at Levi's Stadium: Ticket Down Slashes Ticket Prices on Super Bowl 50 Tickets in Santa Clara, CA at Levi's Stadium 2Health News:Mesothelioma Organization Launches New Store 2Health News:Mesothelioma Organization Launches New Store 3Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 2Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 3Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 2Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 3Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 4Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 5Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 6Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 7
... climate projections and future health vulnerability, overall increases in ... to a recent study by Columbia Universitys Mailman School ... the November 2007 issue of the American Journal of ... a 47 percent to 95 percent increase in summer ...
... Sept. 27 Wyeth (NYSE: WYE ),announced today the ... Directors, effective October 1, 2007. This election increases the number,of ... is Chairman and Chief Executive Officer of International,Flavors & Fragrances ... of the world,s,leading creators of flavors and fragrances used in ...
... Drug mix-ups occur frequently due to packaging and ... Medication errors,continue to rank high (23%) in the ... Reporting System (PA-PSRS). The Patient Safety,Authority highlights the ... September,Patient Safety Advisory., Unclear and confusing labeling ...
... N.C., Sept. 27 North Carolina,students interested in earning the ... Programs Career Conferences on,Optometry sponsored by the N.C. State Education ... -- North Carolina State University (Raleigh, NC) - 1 ... 8, 2007 North Carolina State University in the Talley Student ...
... 100 million years , THURSDAY, Sept. 27 (HealthDay News) ... Earth,s atmosphere 50 million to 100 million years earlier ... reporting in the Sept. 28 issue of the journal ... oxygen levels increased sharply from very low levels during ...
... Sept. 27 454 Life Sciences, a Roche,company, ... used the company,s Genome Sequencer(TM) FLX system to ... mammoths. The study,entitled "Whole-Genome Shotgun Sequencing of Mitochondria ... today in the journal Science. The study ...
Cached Medicine News:Health News:Climate may increase heat-related deaths by 2050s, says Mailman School of PH study 2Health News:Patient Safety Authority Releases Advisory Focusing on Common Causes of Medication Errors 2Health News:Patient Safety Authority Releases Advisory Focusing on Common Causes of Medication Errors 3Health News:Patient Safety Authority Releases Advisory Focusing on Common Causes of Medication Errors 4Health News:Patient Safety Authority Releases Advisory Focusing on Common Causes of Medication Errors 5Health News:Optometry Career Conferences Set for Five N.C. Campuses in October 2Health News:Earth's Oxygen May Have Arrived Earlier 2Health News:454 Sequencing(TM): Science Paper Describes a Novel, Highly Efficient Method of Sequencing Ancient DNA; Sequences the Mitochondria of 10 Individual Mammoths to Prove It 2Health News:454 Sequencing(TM): Science Paper Describes a Novel, Highly Efficient Method of Sequencing Ancient DNA; Sequences the Mitochondria of 10 Individual Mammoths to Prove It 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: